free counter
Health And Medical

Can We Smoke Out Cancer?

On signing the National Cancer Act of 1971, which embodied his arrange for a War on Cancer, President Nixon needed “a national commitment for the conquest of cancer.” In 2016, then-Vice President Biden inaugurated a Cancer Moonshot to accelerate progress against cancer. On February 2 this season, the White House announced that now-President Biden was reigniting the Cancer Moonshot “to lessen the death rate from cancer by at the very least 50% on the next 25 years, and…end cancer once we know it today.” The initiatives of both Presidents centered on research and development of new treatments but additionally included cancer prevention and screening and improved patient care.

Neither Nixon in 1971 nor Biden in 2016 mentioned reducing using tobacco, the leading reason behind cancer death in both women and men. The February 2 Moonshot statement did, however, acknowledge progress against smoking. (Long the best reason behind male cancer mortality, lung cancer surpassed breast cancer because the leading cause of cancer death in ladies in 1987. Even decades later, two-thirds of women still believed breast cancer was the best cause.)

Recently, on June 21, the Biden administration announced plans for what may likely function as most reliable measure ever to lessen smoking: requiring the reduced amount of nicotine in combusted tobacco products to non-addictive levels. This may also be the very best single measure to lessen future cancer mortality.

If seriously pursued, this controversial regulation will ignite a firestorm of opposition from the tobacco industry, tobacco product retailers, philosophical opponents, not to mention many smokers. That opposition implies that implementation won’t occur for a long time, if. (Interestingly, a substantial if uncertain fraction of current smokers supports reducing nicotine to non-addicting levels.)

How significantly might a very-low nicotine regulation impact cancer mortality? We are able to get yourself a feel for the solution by looking back, asking the way the War on Cancer has progressed up to now, and the way the decades-old battle against smoking has affected that progress.

While progress against cancer affects rates of cancer diagnosis, incidence, and 5-year survival, I’ll focus exclusively on arguably the most crucial metric: the cancer death rate. Smoking causes a many cancers, including cancers of the mouth, throat, bladder, kidney, liver, stomach, pancreas, colon and rectum, and cervix. However, I’ll examine only lung cancer, the single largest way to obtain smoking-produced cancer mortality and the main cancer “marker” of smoking. Another cancer sites have several causes (some unknown), while 80-90% of lung cancers are associated with using tobacco and second-hand contact with tobacco smoke.

Adult smoking prevalence has declined substantially since Nixon declared his War on Cancer, from 37% in 1971 to 12.5% in 2020. Both laws and norms impede smoking today, with smoking prohibited in lots of workplaces and public places, and cigarettes increasingly expensive because of increases in manufacturers’ wholesale prices and government excise taxes. Along with reducing smoking prevalence, these factors have significantly reduced the percentage of current smokers who smoke each day, and the amount of cigarettes daily smokers consume. The decreases in the percentage of smokers and the amounts of cigarettes they smoke have produced a sharp decline in a measure that combines both smoking prevalence and daily cigarette consumption: annual adult per capita cigarette consumption (APCCC). Thought as total cigarettes consumed nationwide every year divided by the amount of adults ages 18 and older, APCCC rose dramatically right from the start of the 20th century, when manufactured cigarettes first gained popularity, to 1963, the entire year prior to the first Surgeon General’s report on smoking and health. Smoking fell thereafter, equally dramatically (see figure 1). The stark rise and fall of smoking motivated Harvard historian Allan Brandt to label the 1900s The Cigarette Century.


Because the development of lung cancer follows the onset of smoking decades later, lung cancer was essentially unknown in the first 20th century. Similarly, there exists a lag between a reduction in smoking prevalence and the next reduction in lung cancer. Thus, while adult smoking prevalence began falling in 1964, lung cancer mortality peaked in 1993, nearly 3 decades later.

How gets the turn-around in smoking affected the entire cancer mortality rate? And how is that rate doing independent of decreases in smoking? Figure 2 below shows an extremely encouraging picture of the age-adjusted all-site cancer mortality rate.


Cancer mortality overall rose through the 1980s. For both sexes combined, the cancer mortality rate peaked in 1991. The rate for women also peaked that year. For men, the rate peaked per year earlier. From their peak rates to 2019, the all-site cancer death rate dropped 32.1% for both sexes combined: 28.2% for women and 38.2% for men. By any measure, it is a terrific accomplishment.

Figure 3 shows changes in the lung cancer mortality rate through the same period. The rate rose through 1990 for men, exactly the same year that all-site cancer mortality peaked for men. For women, in comparison, the lung cancer rate increased through 2002. The 12-year gap between your sexes’ peak rates — and women’s lower peak rate — reflect women’s having started smoking later than men, never reaching men’s higher smoking prevalence rates, and beginning to quit later aswell. Male smoking prevalence peaked in the 1950s, with an increase of than 1 / 2 of all men smoking, and remained fairly steady through the first 1960s. Female smoking prevalence increased before 1964 Surgeon General’s report, which interrupted that upward trend. Smoking prevalence reached just over a third for women. The lung cancer mortality rate for women and men combined peaked in 1993. By 2019, the lung cancer mortality rate for both sexes had dropped by 43.5%. For women, the rate fell 32.5%. For men, the rate plummeted by 55.7%.


Examining the reduction in all-site cancer mortality except for lung cancer, from 1991 once the all-site rate peaked, the drop was 27% for both sexes combined, or 19.7% for women and 29.8% for men.

Do you know the take-home messages? First, with all-site age-adjusted cancer mortality increasing through 1991, President Nixon, who died in 1994, barely lived to see his War on Cancer turn the corner. But turn the corner it did, with cancer mortality having dropped through 2019 by way of a third. Importantly, the increase and reduction in cancer mortality moved virtually in tandem with the increase and reduction in lung cancer mortality, especially male lung cancer. The drop in smoking — and therefore in lung cancer — has contributed mightily to the impressive decline in overall cancer mortality. Most strikingly, the reduction in the male lung cancer death rate makes up about almost half (47%) of the reduction in the male all-site cancer death rate. Needless to say, not absolutely all lung cancer deaths are due to smoking — as much as 20% aren’t — but offsetting that consideration may be the proven fact that decreases in smoking take into account decreases in cancers of multiple other sites aswell.

Another important message: Independent of progress against smoking, we’ve made substantial progress against cancer mortality, reflecting other styles of prevention, better screening and early diagnosis, and better treatment.

The 3rd message: President Biden’s ambitious cancer mortality goal can be done. Reducing the cancer death rate by half on the next 25 years will demand greater success compared to the decrease of days gone by 25 years. It’ll be determined by continuing improvements in early diagnosis and treatment of cancer. Also it may be determined by the power of President Biden’s administration (and likely that of his successor) to withstand enormous political and legal pressure in wanting to implement a very-low nicotine regulation. If the stars align, we may just be in a position to shoot the moon.

Kenneth E. Warner, PhD, may be the Avedis Donabedian Distinguished University Professor emeritus and dean emeritus at the University of Michigan School of Public Health.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker